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Threlfall et al in this issue present direct evidence, for the first time,
that the UK breast screening programme (NHSBSP) is reducing breast
cancer mortality. As such it makes a valuable addition to the less direct
approaches: one adopted by Blanks et al (2001) in their analysis of the
different contributions to the decline in breast cancer mortality seen
nationally, and another by McCann et al (2001) in their modelling of
the likely impact on future breast cancer mortality of the change
brought about by the NHSBSP in prognostic characteristics of breast
cancer recorded at diagnosis. Viewed internationally, it adds to the
results from Sweden (Tabar et al, 2003) and The Netherlands (Otto
et al, 2003), which together have provided a powerful recent demon-
stration that routine mammography screening has reduced population
breast cancer mortality rates. Taken together, these results confirm the
conclusion from the Swedish randomized trials (World Health
Organization. International Agency for Research on Cancer, 2002)
that mammographic screening is an effective means of reducing breast
cancer mortality, and show that the results from the more intensive
setting of a randomized trial can be replicated in the service setting.
Besides documenting a decline in breast cancer mortality, the
Threlfall et al paper shows that the degree of benefit from a breast
screening programme is highly dependent on its quality. This, in turn,
is determined by the degree of population coverage achieved and the
quality of the screening. The latter is a complex issue, but two
relatively simple closely related measures are the detection rate of
small cancers (less than 10 or 15mm in diameter) and the rate of
interval cancers in each of the 3 years in the interscreening interval,
both expressed as a multiple of the underlying breast cancer incidence
rates. The authors focus on the first of these measures. The higher
screening uptake rates in Wigan than in Manchester are reflected in
greater reduction both in breast cancer mortality and in the incidence
of advanced cancers. The difference, however, in the mortality rate
reduction between the two programmes is more than could reasonably
be attributed to the difference in uptake, assuming that uptake and
mortality reduction are linearly related. There is also a greater
detection rate of breast cancer at screening in the Wigan programme,
particularly of small cancers. High sensitivity for the detection of small
cancers is crucial, since the mortality reduction by screening is a
consequence of diagnosing cancers earlier, and hence when smaller,
survival improving by more than the lead-time associated with
screening. In the first years of the NHSBSP, emphasis was placed on
avoiding harm from screening, using easily measurable indicators such
as the rate of recall for further assessment or the number of negative
biopsies performed. Important as the avoidance of harm is, breast
screening is pointless, even unethical, if the primary aim of detecting
small cancers is not met. The recent results point clearly to the basic
breast screening equation relating the mortality reduction to the extent
to which diagnosis is brought forward in time.
Three years ago, discussion of this subject was hijacked by a review of
the published trials, purporting to demonstrate that the major trials
demonstrating the efficacy of breast screening were seriously flawed
(Gotzsche and Olsen, 2000), later given the status of a Cochrane review
(Olsen and Gotzsche, 2001). Major shortcomings in this review were
clearly described, in the authoritative assessment of breast screening
provided by a WHO workshop (World Health Organization. Interna-
tional Agency for Research on Cancer, 2002). It is unfortunate that the
organization responsible for Cochrane reviews made no attempt to
redress the damage done by this flawed review. The results of Threlfall
et al, together with the Swedish work, now move the position forward.
The question is not whether breast screening works, but how best to
ensure that the benefits of a population screening programme can be
brought up to the level of benefit achieved in the trials. This requires
constant monitoring. Mammography screening may never make the
major impact on breast cancer mortality that cervical cytology screening
has made on cervical cancer mortality. It has the potential, however, to
make a substantial reduction in breast cancer mortality, a potential now
clearly being realised. Together with widespread dissemination of
improved treatment modalities and greater awareness of the benefits of
early diagnosis, the NHSBSP should make an increasing contribution in
the next few years to reduction in breast cancer deaths, continuing the
marked decline in breast cancer mortality seen over the past decade.
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